{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"509","value":"1260"},{"groupId":"OG002","spread":"272","value":"955"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Cycle 1, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"688","value":"1500"},{"groupId":"OG002","spread":"554","value":"1260"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 3, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"404","value":"1030"},{"groupId":"OG002","spread":"340","value":"953"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Cycle 1, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"507","value":"1860"},{"groupId":"OG002","spread":"754","value":"1680"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 3, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"366","value":"979"},{"groupId":"OG002","spread":"429","value":"886"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"title":"Cycle 1, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"678","value":"1420"},{"groupId":"OG002","spread":"809","value":"1280"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"13"}],"units":"Participants"}],"title":"Cycle 3, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"329","value":"963"},{"groupId":"OG002","spread":"350","value":"1070"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 1, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"732","value":"1400"},{"groupId":"OG002","spread":"729","value":"1380"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 3, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"379","value":"1180"},{"groupId":"OG001","spread":"807","value":"2010"},{"groupId":"OG002","spread":"234","value":"1150"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 1, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1090","value":"1710"},{"groupId":"OG001","spread":"1210","value":"2800"},{"groupId":"OG002","spread":"578","value":"1530"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 3, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUC calculation.","dispersionType":"Standard Deviation","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 and who had at least one serum sample providing evaluable PK data.","reportingStatus":"POSTED","timeFrame":"pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).","title":"Phase 2: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LAG525","type":"SECONDARY","unitOfMeasure":"day*ug/mL"}